A novel breakthrough in wrist-worn transdermal troponin-I-sensor assessment for acute myocardial infarction.

Aims: Clinical differentiation of acute myocardial infarction (MI) from unstable angina and other presentations mimicking acute coronary syndromes (ACS) is critical for implementing time-sensitive interventions and optimizing outcomes. However, the diagnostic steps are dependent on blood draws and laboratory turnaround times. We tested the clinical feasibility of a wrist-worn transdermal infrared spectrophotometric sensor (transdermal-ISS) in clinical practice and assessed the performance of a machine learning algorithm for identifying elevated high-sensitivity cardiac troponin-I (hs-cTnI) levels in patients hospitalized with ACS. Methods and results: We enrolled 238 patients hospitalized with ACS at five sites. The final diagnosis of MI (with or without ST elevation) and unstable angina was adjudicated using electrocardiography (ECG), cardiac troponin (cTn) test, echocardiography (regional wall motion abnormality), or coronary angiography. A transdermal-ISS-derived deep learning model was trained (three sites) and externally validated with hs-cTnI (one site) and echocardiography and angiography (two sites), respectively. The transdermal-ISS model predicted elevated hs-cTnI levels with areas under the receiver operator characteristics of 0.90 [95% confidence interval (CI), 0.84-0.94; sensitivity, 0.86; and specificity, 0.82] and 0.92 (95% CI, 0.80-0.98; sensitivity, 0.94; and specificity, 0.64), for internal and external validation cohorts, respectively. In addition, the model predictions were associated with regional wall motion abnormalities [odds ratio (OR), 3.37; CI, 1.02-11.15; P = 0.046] and significant coronary stenosis (OR, 4.69; CI, 1.27-17.26; P = 0.019). Conclusion: A wrist-worn transdermal-ISS is clinically feasible for rapid, bloodless prediction of elevated hs-cTnI levels in real-world settings. It may have a role in establishing a point-of-care biomarker diagnosis of MI and impact triaging patients with suspected ACS.

Management of American Heart Association/American College of Cardiology-Defined Stage 2 Hypertension by Cardiologists in India.

Uncontrolled hypertension is an important cardiovascular risk factor and therefore requires effective approaches to patient management. This study assessed approaches to the management of patients with Stage 2 hypertension by cardiologists in India. This was a retrospective, multicenter, observational, case-based questionnaire study. Data on demographic characteristics, risk factors associated with Stage 2 hypertension, use of antihypertensive medications, side effects, and approaches to education for 2,540 patients were extracted from questionnaire responses provided by 508 cardiologists. The study population of patients with Stage 2 hypertension had a mean age of 55.0 years. Most of the patients (62.6%) were aged 30 to 60 years and diabetes mellitus was the most prevalent comorbidity (48.9%). Triple antihypertensive therapy was being used by 760 patients, and 634 and 1,146 patients were receiving 4 and 5 different antihypertensive medications, respectively. Telmisartan, amlodipine, chlorthalidone, hydrochlorothiazide, spironolactone, metoprolol, and prazosin were the commonly prescribed drugs. Ankle edema (27.7%) was the most frequent side effect of therapy. Pharmacotherapy was supported by patient education and lifestyle modifications for better blood pressure control. The standardized approach to the collection and assessment of these contemporary data provides useful insights into the characteristics and treatment of patients with Stage 2 hypertension in India.

Effects of percutaneous balloon mitral valvuloplasty on left ventricular deformation in patients with isolated severe mitral stenosis: a speckle-tracking strain echocardiographic study.

BACKGROUND: Previous studies have reported abnormal left ventricular (LV) contraction in patients with mitral stenosis (MS). The aim of this study was to explore the serial changes in LV mechanics in patients with severe MS undergoing balloon mitral valvuloplasty (BMV) to understand the reversibility and determinants of abnormal LV contractile function. METHODS: Fifty-seven patients with severe MS and 19 healthy controls underwent echocardiographic examinations, including two-dimensional speckle-tracking-based LV global longitudinal strain (GLS) and global circumferential strain measurements. In patients with MS, the same measurements were repeated 72 hours after BMV. RESULTS: In comparison with controls, patients with MS had faster heart rates and lower LV end-diastolic volumes and LV ejection fractions (P = .008). The magnitudes of both GLS and global circumferential strain were reduced in patients with MS (P < .001 for both), with 48 patients (84.2%) having GLS below the 25th percentile of controls. BMV resulted in significant improvements in GLS and global circumferential strain (-14.6 ± 3.3% vs -17.8 ± 3.5% and -20.0 ± 5.0% vs -22.5 ± 4.6%, respectively, P < .005 for both). On multivariate analysis, left atrial volume, mean transmitral gradient, and LV end-diastolic volume were independently correlated with baseline GLS, whereas increment in LV end-diastolic volume was the only determinant of increased GLS after BMV. CONCLUSIONS: LV deformation is reduced in patients with severe MS and is related to the hemodynamic severity of MS. BMV results in rapid improvement of LV deformation, which is correlated with serial improvement in LV diastolic loading. These findings suggest that reduced LV diastolic filling rather than an irreversible myocardial structural abnormality contributes predominantly to reduced LV mechanical performance in patients with MS.

Journey from clinical practice to clinical research.

We have experienced a significant change into 'the way we practice' since we stepped into the area of clinical research. The training in good clinical practice (GCP) made us capable of imparting the excellence. We describe the experience of our journey from clinical practice to clinical research.